Published in Immunol Lett on July 23, 2007
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA (2009) 1.07
Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets (2010) 1.02
DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. Cell Mol Neurobiol (2011) 1.02
Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease. Vaccine (2010) 1.00
Advances in the development of vaccines for Alzheimer's disease. Discov Med (2013) 0.97
A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease. J Neuroimmunol (2012) 0.94
Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen. Genet Vaccines Ther (2009) 0.93
Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques. Alzheimers Dement (2013) 0.92
Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology. J Alzheimers Dis (2011) 0.90
Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets (2009) 0.89
DNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB/c mice. BMC Infect Dis (2013) 0.86
Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant. Int J Nanomedicine (2013) 0.86
Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease. Transl Neurosci (2012) 0.83
Simvastatin enhances immune responses to Aβ vaccination and attenuates vaccination-induced behavioral alterations. Brain Res (2010) 0.78
Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease. Immunotargets Ther (2013) 0.78
Neuroendocrine immunomodulation network dysfunction in SAMP8 mice and PrP-hAβPPswe/PS1ΔE9 mice: potential mechanism underlying cognitive impairment. Oncotarget (2016) 0.76
Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease. J Neuroimmunol (2012) 0.76
Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging. Oncotarget (2016) 0.75
Multiple cytokines are involved in the early events leading to the Alzheimer's disease pathology. Tottori Rinsho Kagaku Kenkyukai Shi (2008) 0.75
SAG4 DNA and Peptide Vaccination Provides Partial Protection against T. gondii Infection in BALB/c Mice. Front Microbiol (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med (1998) 4.13
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol (2004) 3.01
Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology (2005) 2.79
Advances in tuberculosis vaccine strategies. Nat Rev Microbiol (2006) 2.75
Development of TLR9 agonists for cancer therapy. J Clin Invest (2007) 2.64
Jump-starting the immune system: prime-boosting comes of age. Trends Immunol (2004) 2.61
Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33
Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol (2000) 2.30
Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25
Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol (2005) 2.05
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02
Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol (2003) 1.81
Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A (1998) 1.81
Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol (2004) 1.78
Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol (2003) 1.60
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol (2005) 1.56
Immunotherapeutic approaches to Alzheimer's disease. Science (2003) 1.52
Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol (2005) 1.47
Therapeutic approaches to Alzheimer's disease. Brain (2006) 1.34
Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol (2006) 1.28
Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol (2003) 1.27
Current progress in beta-amyloid immunotherapy. Curr Opin Immunol (2004) 1.18
Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.17
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine (2005) 1.09
alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res (2001) 1.07
Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol (2005) 1.05
DNA vaccination against tumors. J Gene Med (2005) 1.03
AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. Biotechniques (2001) 1.03
Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer (2005) 1.02
Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol Aging (2006) 1.01
Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc Natl Acad Sci U S A (2006) 0.97
Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J Gene Med (2007) 0.96
Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol Ther (2007) 0.95
New directions towards safer and effective vaccines for Alzheimer's disease. Curr Opin Mol Ther (2005) 0.93
Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting. J Infect Dis (2005) 0.92
Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther (2005) 0.92
The adenovirus inverted terminal repeat functions as an enhancer in a cell-free system. J Biol Chem (1989) 0.90
Vaccination against gonadotropin-releasing hormone (GnRH) using toxin receptor-binding domain-conjugated GnRH repeats. Cancer Res (2000) 0.89
Inverted terminal repeat sequences of adeno-associated virus enhance the antibody and CD8(+) responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera. Virology (2004) 0.88
Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. Biochem Biophys Res Commun (2005) 0.88
Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. Neurobiol Dis (2006) 0.87
Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF. Vaccine (2005) 0.86
Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine (2006) 0.83
Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates. DNA Cell Biol (2006) 0.82
Immunotherapy of Alzheimer disease. Alzheimer Dis Assoc Disord (2004) 0.82
A DNA vaccine containing inverted terminal repeats from adeno-associated virus increases immunity to HIV. J Gene Med (2003) 0.78
Role of toll-like receptor signalling in Abeta uptake and clearance. Brain (2006) 2.70
Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2008) 1.67
Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging (2005) 1.32
TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflammation (2011) 1.26
Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am J Pathol (2003) 1.14
Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis (2006) 1.04
Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J Gene Med (2007) 0.96
MyD88 deficiency ameliorates β-amyloidosis in an animal model of Alzheimer's disease. Am J Pathol (2011) 0.93
Methyl-CpG binding protein 2 gene (MECP2) variations in Japanese patients with Rett syndrome: pathological mutations and polymorphisms. Brain Dev (2005) 0.89
Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. Biochem Biophys Res Commun (2005) 0.88
Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model. J Alzheimers Dis (2011) 0.86
Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain. Neurosci Lett (2004) 0.84
Simvastatin enhances immune responses to Aβ vaccination and attenuates vaccination-induced behavioral alterations. Brain Res (2010) 0.78
Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model. J Mol Neurosci (2012) 0.77
Association of the GNAS1 gene variant with hypertension is dependent on alcohol consumption. Hypertens Res (2003) 0.77
Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease. J Neuroimmunol (2012) 0.76
Genome-wide linkage disequilibrium mapping of hypertension in Japan. Hypertens Res (2003) 0.75